Ariad Pharmaceuticals Inc fka ARIA

[biotech_researcher]

Rachel McMinn is absolutely clueless as a research analyst and has missed the entire 140% move up in Ariad over the last year, and is still neutral. Her client(s) are going to miss the next $10 in share price appreciation of Ariad as well. When she is finally in, I'm out.. disgusting.. All imho, of course...